Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial

•The pathophysiology of SARS-CoV-2 infection may be attributed to cytokine release syndrome.•In this syndrome, interleukin 6 is released after the activation of the inflammatory cascade.•The mortality rate in the current study was 16%.•Tocilizumab may be a promising agent to decrease the mortality rate in severe or critical SARS-CoV-2 infection.